A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
about
Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and ValidationSulforaphane Preconditioning Sensitizes Human Colon Cancer Cells towards the Bioreductive Anticancer Prodrug PR-104APhase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.The Activity of SN33638, an Inhibitor of AKR1C3, on Testosterone and 17β-Estradiol Production and Function in Castration-Resistant Prostate Cancer and ER-Positive Breast Cancer.AKR1C3 is a biomarker of sensitivity to PR-104 in preclinical models of T-cell acute lymphoblastic leukemiaPre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.A single nucleotide polymorphism genotyping platform for the authentication of patient derived xenografts.DNA Adduct Profiles Predict in Vitro Cell Viability after Treatment with the Experimental Anticancer Prodrug PR104A.Hypoxia-activated prodrugs: paths forward in the era of personalised medicine.Phenotypic and metabolic investigation of a CSF-1R kinase receptor inhibitor (BLZ945) and its pharmacologically active metabolite.Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL.AKR1C enzymes sustain therapy resistance in paediatric T-ALL.
P2860
Q26784048-6CAD9E99-3C75-469E-9D61-8D71DF545EBDQ28550585-EADBE2A5-DFAC-416D-961A-2DCDAC1DCCFFQ33420436-C99E2418-434E-4ECB-AB6F-69D18353FFC7Q33770742-601258DE-CA6B-4DDF-9950-B7C2FA07A27FQ34482552-897B3A8F-20A9-478E-A8C4-B246F898FE33Q36212847-62B0CEF5-F198-4AB3-BBE8-C34DC8EAA658Q37645045-9F21B5D5-3653-4322-A977-76B5F4D95D6BQ37717094-AFE7EFDD-D575-4BD8-83FA-F9062ABE9277Q38806173-9DB4CB7D-03EE-462E-B5A3-55C0184BAC81Q38960521-A2303274-2422-4A47-99AA-7D6C63CEE19CQ50209854-3736426E-6FCA-4124-BA4A-F8FABEB22AF6Q53703893-36556831-7ABA-4B25-B389-B8EEE40AF947
P2860
A novel fluorometric assay for aldo-keto reductase 1C3 predicts metabolic activation of the nitrogen mustard prodrug PR-104A in human leukaemia cells.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A novel fluorometric assay for ...... 104A in human leukaemia cells.
@ast
A novel fluorometric assay for ...... 104A in human leukaemia cells.
@en
A novel fluorometric assay for ...... 104A in human leukaemia cells.
@nl
type
label
A novel fluorometric assay for ...... 104A in human leukaemia cells.
@ast
A novel fluorometric assay for ...... 104A in human leukaemia cells.
@en
A novel fluorometric assay for ...... 104A in human leukaemia cells.
@nl
prefLabel
A novel fluorometric assay for ...... 104A in human leukaemia cells.
@ast
A novel fluorometric assay for ...... 104A in human leukaemia cells.
@en
A novel fluorometric assay for ...... 104A in human leukaemia cells.
@nl
P2093
P50
P1476
A novel fluorometric assay for ...... 104A in human leukaemia cells.
@en
P2093
Annika Foehrenbacher
Donya Moradi Manesh
Jad El-Hoss
Jeffrey B Smaill
Juliana Benito
Marina Konopleva
Stephen M F Jamieson
Susan M Pullen
William R Wilson
P356
10.1016/J.BCP.2013.12.019
P407
P50
P577
2014-01-13T00:00:00Z